Allogeneic stem cell transplantation for persons living with HIV (SFGM-TC)

People living with HIV (PLWH) experienced an increased risk of heme malignancies. The place of cellular therapy as consolidation is well established in the general population, but remains to be confirmed in PLWH. Control of HIV has dramatically been improved due to combined antiretroviral therapy, and continuation of the treatment all through the graft procedure resulted in survival and TRM comparable with the general population. So, PLWH with an indication of auto- or allo-graft must be referred as eligible for the procedure. The conditioning regimen depends mainly on the malignancy and comorbidities. In allograft setting, the choice of the donor and the stem cell source must follow standard rules. Moreover, eradication of HIV has been described in patients allografted with a donor homozygous for CCR5 delta 32 mutation, due to a Graft vs. Reservoir effect independent of the myeloablation. If available, the selection of a donor bearing this mutation must be favoured. The antiretroviral therapy must be continued all along the treatment procedure after discussion with an expert for the choice of the antivirals. Prophylaxies against GVHD and management of infectious complications have to be followed according to standard rules.

Published by Bulletin du cancer, 2026. The guideline itself is at the source linked here.

doi.org/10.1016/j.bulcan.2026.03.003